Nine Chapters Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Nine Chapters Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-31,500	Closed	-$130K	–	1027
2015 Q2	$130K	Buy	+31,500	New	+$126K	0.01%	855
2014 Q4	–	Sell	-10,900	Closed	-$36K	–	984
2014 Q3	$36K	Buy	+10,900	New	+$28.5K	﹤0.01%	962

Other funds holding CPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nine Chapters Capital Management's CPRX Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2015, closing a stake of 31,500 shares — an estimated $130K sold.

Nine Chapters Capital Management first reported a position in CPRX in Q3 2014 and held it in 2 quarters. The position peaked at $130K in Q2 2015. 90 funds tracked by Wall St. Rank hold CPRX as of Q3 2015.

Nine Chapters Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 31,500 Catalyst Pharmaceutical shares in Q3 2015, an estimated $130K.
Nine Chapters Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 2 quarters.
Nine Chapters Capital Management's Catalyst Pharmaceutical position peaked at $130K in Q2 2015.
90 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.